Pandemic Watch
Zaire ebolavirus vs Bundibugyo ebolavirus
A factual side-by-side comparison of two ebolavirus species: Zaire ebolavirus and Bundibugyo ebolavirus. Reservoir biology, geographic distribution, clinical course, case-fatality rate, and outbreak history.
Discovery and history
Zaire ebolavirus
Zaire ebolavirus was first isolated in 1976 during a near-simultaneous pair of outbreaks: one near the Ebola River in northern Zaire (now the Democratic Republic of the Congo), and another in southern Sudan that was initially assumed to be the same virus but turned out to be a distinct species (now Sudan ebolavirus). The Zaire outbreak in Yambuku, traced largely to a Catholic mission hospital that re-used unsterilized needles for antenatal injections, killed 280 of 318 reported cases — an 88 percent case-fatality rate that set the early reputation of Ebola as among the most lethal known viral infections. The virus was named for the river to avoid stigmatizing the village itself.
Bundibugyo ebolavirus
In late 2007, clinicians at Bundibugyo Hospital in western Uganda began reporting an unexplained hemorrhagic fever. Initial laboratory testing assumed Sudan ebolavirus — the species most recently documented in the region — but PCR amplicons sequenced at the CDC produced an unexpected result: the virus shared roughly 70 percent of its genome with the other ebolaviruses, sufficiently divergent to warrant a new species designation. The pathogen was named for the district where the outbreak occurred. The outbreak ultimately produced 149 reported cases and 37 deaths.
Reservoir and ecology
Zaire ebolavirus
The natural reservoir is strongly suspected but not definitively confirmed to be fruit bats of the family Pteropodidae — in particular Hypsignathus monstrosus (hammer-headed bat), Epomops franqueti (Franquet's epauletted fruit bat), and Myonycteris torquata (little collared fruit bat). Serological evidence of ebolavirus exposure in these species has been documented across the Congo Basin and West Africa. Spillover into humans is thought to occur both directly (contact with bat saliva, urine, or droppings, often via fruit bats roosting in trees or buildings) and indirectly (hunting and butchering primates or other forest mammals that have themselves been infected by bat material). Once a spillover occurs, the human-to-human transmission cycle takes over and the wildlife reservoir is no longer epidemiologically relevant for the duration of the outbreak.
Bundibugyo ebolavirus
As with the other ebolavirus species, the natural reservoir is strongly suspected to be fruit bats of family Pteropodidae but has not been definitively confirmed. The geographic overlap with Sudan ebolavirus across the Uganda-DRC border suggests overlapping reservoir ranges. Spillover into humans is presumed to occur through the same pathways: direct contact with infected bats or with primates and other forest mammals exposed to bat material.
Clinical course
Zaire ebolavirus
Ebola virus disease begins after an incubation period of two to twenty-one days (typically eight to ten) with sudden fever, severe headache, myalgia, fatigue, and pharyngitis. Within several days patients develop vomiting, watery diarrhea, abdominal pain, and a maculopapular rash. The volume of fluid loss is extreme — patients with severe disease can lose five to ten liters per day to diarrhea, driving profound electrolyte derangements and hypovolemic shock. Hemorrhagic manifestations (petechiae, conjunctival hemorrhage, bleeding from venipuncture sites, gastrointestinal bleeding) appear in roughly half of severe cases. Death, when it occurs, is typically between days seven and sixteen and is driven by hemorrhagic shock, multi-organ failure, or both. Case-fatality has ranged from 44 percent in the 2014-2016 West Africa epidemic to 88 percent in early outbreaks — the variability tracks closely with access to early supportive care, particularly aggressive intravenous fluid and electrolyte replacement.
Bundibugyo ebolavirus
Clinical course follows the broader ebolavirus pattern: an incubation of 2-21 days, a febrile prodrome with severe headache and myalgia, progression to severe gastrointestinal symptoms (vomiting, watery diarrhea), and a subset of patients developing hemorrhagic manifestations and multi-organ failure. The notable difference is the case-fatality rate: 25 to 40 percent for Bundibugyo virus across documented outbreaks, materially lower than Sudan or Zaire. The reasons are not fully understood — host genetics, viral virulence factors, and improved early supportive care have all been proposed contributors.
Notable outbreaks
Zaire ebolavirus
The 1976 Yambuku outbreak in Zaire (318 cases, 280 deaths) was the original Ebola event. The 1995 Kikwit outbreak in DRC (315 cases, 254 deaths) brought Ebola into wider international consciousness and triggered the first systematic infection-control response by an international team. The 2000 Gulu outbreak in northern Uganda spread to healthcare workers and produced 425 cases — although that outbreak was Sudan ebolavirus rather than Zaire. The defining Zaire ebolavirus event is the 2014 to 2016 West Africa epidemic: 28,616 reported cases, 11,310 deaths across Guinea, Sierra Leone, and Liberia, and the first ebolavirus exportation to the United States and Europe. The 2018 to 2020 North Kivu outbreak in DRC was the second-largest Ebola event ever (3,481 cases, 2,299 deaths) and saw the first widespread deployment of the rVSV-ZEBOV vaccine under a ring-vaccination strategy.
Bundibugyo ebolavirus
The 2007 Bundibugyo Uganda outbreak (149 cases, 37 deaths) was the discovery event and the largest until 2026. The 2012 Isiro DRC outbreak (52 cases, 25 deaths) confirmed cross-border circulation. The 2026 DRC/Uganda outbreak — currently tracked on this site's dashboard — is the largest Bundibugyo virus event recorded, with international spread to Kampala via a confirmed imported case from DRC. WHO declared the 2026 outbreak a Public Health Emergency of International Concern on May 16, 2026.
Prevention
Zaire ebolavirus
The licensed vaccine Ervebo (rVSV-ZEBOV) protects against Zaire ebolavirus and is the cornerstone of outbreak response. WHO's ring-vaccination strategy — immunizing contacts of confirmed cases and contacts of contacts within days of identification — has interrupted transmission chains in DRC outbreaks since 2018. Beyond vaccination, infection prevention and control in healthcare facilities (PPE, isolation, dedicated Ebola treatment units) and safe-burial protocols (avoiding traditional washing of bodies, which exposes funeral attendees to the virus) are the two highest-impact non-pharmaceutical interventions. Survivor follow-up matters as well: Zaire ebolavirus persists in immune-privileged sites (eye, central nervous system, testis) for months in some survivors and can cause flare cases and onward transmission long after the original outbreak is declared over.
Bundibugyo ebolavirus
No licensed vaccine specifically against Bundibugyo virus exists. The Ervebo (rVSV-ZEBOV) vaccine targets Zaire ebolavirus only and provides no demonstrated cross-protection against Bundibugyo. Several candidate trivalent vaccines (covering Zaire, Sudan, and Bundibugyo simultaneously) are in development and have been deployed under emergency-use protocols during the 2026 PHEIC. Outside of vaccination, the response leans on the same fundamentals as other ebolavirus outbreaks: contact tracing, dedicated treatment units, safe-burial practices, and rigorous infection prevention and control in healthcare settings.
Full strain profiles: Zaire ebolavirus · Bundibugyo ebolavirus. For the broader disease guide, see ebola.
